Literature DB >> 18854272

Accuracy of Papanicolaou smears in cervical cancer patients treated with radiochemotherapy followed by radical surgery.

Gian Franco Zannoni1, Valerio Gaetano Vellone.   

Abstract

Papanicolaou (Pap) smears are part of the follow-up program for patients with cervical cancer treated with radiochemotherapy. After therapy, residual neoplastic cells may be rare, seldom exfoliate, and may demonstrate many alterations, which creates a risk of inaccurate results. We report a study of 65 patients who received radiochemotherapy before radical surgery. For each patient, we compared smear results with results from histologic examination of the whole cervix. The Pap smear was "negative for cancer" in 50 cases, "positive for cancer" in 6 cases, and detected atypical squamous cells of undetermined significance in 9 cases. Histologic examination revealed a complete pathologic response (pR0) in 26 cases and a partial pathologic response (pR1) in 27. In 12 cases, no pathologic response (pR2) was shown. Comparison of these results showed that the Pap test had a sensitivity of 0.16, a specificity of 0.96, a negative predictive value of 0.83, a positive predictive value of 0.42, and an accuracy of 0.46.

Entities:  

Mesh:

Year:  2008        PMID: 18854272     DOI: 10.1309/AJCPP1ZWK8EMHBCZ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Cervicovaginal cytology in patients undergoing pelvic radiotherapy using the Focalpoint system: results from the RODEO study.

Authors:  Maíra Degiovani Stein; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Adhemar Longatto-Filho
Journal:  Diagn Pathol       Date:  2015-01-16       Impact factor: 2.644

2.  Comparative study between liquid-based cytology & conventional Pap smear for cytological follow up of treated patients of cancer cervix.

Authors:  Uma Singh; Sabuhi Qureshi; Neha Negi; Nisha Singh; Madhumati Goel; Kirti Srivastava
Journal:  Indian J Med Res       Date:  2018-03       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.